Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 2351–2400 of 18397
The Board appointed the Company’s Chief Executive Officer, Barry Gosin, as Principal Executive Officer of the Company following Howard Lutnick’s confirmation as the 41st Secretary of Commerce and departure from the Company.
Howard Lutnick, Chairman of the Board of Directors (the “Board”) and Chief Executive Officer of BGC Group, Inc. (“BGC” or the “Company”), informed the Company that he has stepped down as Chairman of the Board and Chief Executive Officer of the Company, effective February 18, 2025
Stephan Paulo Gratziani, the Company’s current President, was appointed as the Company’s Chief Executive Officer, effective May 1, 2025
On the same day, the Board of Directors (the “Board”) of the Company appointed Bonnie-Jeanne Gerety as Interim Chief Executive Officer.
On February 14, 2025, in connection with the Company’s ongoing bankruptcy cases, the Board made the decision to terminate all Company employees, including all executive officers except for Winston Mar of CR3 Partners, the Company’s Chief Restructuring Officer.
As of February 12, 2025, The Board of Directors of PNXP accepted the Resignation of Mr. Matthew Feinstein as Chief Executive Officer "CEO", President, Directors and Chairman of the Board.
As of February 12, 2025, The Board of Directors of PNXP accepted the appointment of Mr. Franjose "Frank" Yglesias as Chief Executive Officer "CEO", President, Directors and Chairman of the Board.
the Board appointed Paul Edmondson as interim Chief Executive Officer.
terminated the employment of Sara Silverstein, the Company’s Chief Executive Officer, without cause, effective the same day.
(As previously announced, Mr. Spiegel will transition from his role as Chief Financial Officer on March 1, 2025.)
Appointment of John H. Lee as Chief Financial Officer On February 13, 2025 , NerdWallet, Inc. (the Company) appointed Jun Hyung Lee (aka John H. Lee) (age 39) as Chief Financial Officer (CFO) of the Company, effective March 17, 2025.
The Company has appointed Nicholas Tatum (age 40), the Company’s Corporate Controller, as Chief Accounting Officer and principal accounting officer, effective March 8, 2025.
On February 13, 2025, the Company appointed Chao Li to serve as Chief Financial Officer of the Company.
On February 13, 2025, the Company appointed Juan Yang to serve as Chief Executive Officer, Treasurer and Secretary of the Company.
will transition from his role as Chief Financial Officer on March 1, 2025.
Under the Consulting and Transition Agreement, Mr. Akright will serve as a fractional Chief Financial Officer to the Company, and will continue to serve as the Company's principal financial and accounting officer.
Mr. Sarner resigned from his positions of Chief Financial Officer, Chief Compliance Officer and Secretary of the Company, effective immediately.
the Board also promoted Chris Rehberger, Executive Vice President of Finance and Treasurer of the Company, to the positions of Chief Financial Officer, Treasurer and Secretary of the Company, effective immediately.
Bowen S. Diehl notified the Board that he was stepping down as the President and Chief Executive Officer of the Company and as a director of the Board.
On February 17, 2025, the Board appointed Michael S. Sarner, the Chief Financial Officer, Chief Compliance Officer and Secretary of the Company, to succeed Mr. Diehl as the President and Chief Executive Officer of the Company, effective immediately.
On February 14, 2025, the Board elected Mr. Mike Stepniak, age 47, to serve as the Company’s Senior Vice President and Chief Financial Officer, effective as of February 17, 2025.
On February 14, 2025, the Board appointed Martin Rodgers to the position of Chief Financial Officer of the Company.
On February 14, 2025, Mr. Umesh Mahajan, Co-Chief Investment Officer, Chief Financial Officer and Secretary of the Company, resigned from his position as Chief Financial Officer of the Company.
Katrina Sparano retired as the Company’s Chief Financial Officer and Treasurer effective February 15, 2025.
Kaitlyn O’Neil was appointed as the Company’s new Principal Financial Officer and Treasurer, effective such date.
Effective February 13, 2025, Milton H. Werner, Ph.D. resigned as President, Chief Executive Officer and principal executive officer of Inhibikase Therapeutics, Inc. (the “Company”) and as a member of the Board of Directors (the “Board”) of the Company (the “Resignation”).
Effective February 14, 2025, the Board appointed Mark Iwicki as President, Chief Executive Officer and principal executive officer of the Company (the “Appointment”).
Mr. LaRose became a full-time non-officer employee of the Company, and is expected to remain employed for a transition period ending on April 30, 2025.
appointed Sabrina Simmons to succeed Brian LaRose as the Company’s Chief Financial Officer (the “CFO Succession”), effective as of February 17, 2025
On February 14, 2025, the Board appointed Frank Karbe, 56, as the Company’s Chief Financial Officer (including as its principal financial officer and principal accounting officer), effective as of Mr. Karbe’s employment start date, which is expected to be February 24, 2025
On February 12, 2025, Cidara Therapeutics, Inc. (the “Company”) and Preetam Shah, Ph.D., MBA., the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, mutually agreed to Dr. Shah’s separation from such roles with the Company, effective February 24, 2025
Mr. Adamson will succeed Jeremy Thigpen, who has led Transocean as Chief Executive Officer since 2015.
Keelan Adamson, the Company’s President and Chief Operating Officer, will become President and Chief Executive Officer following a transition period, which is expected to conclude during the second quarter of 2025.
Michael D. Farkas (aged 52) was appointed Chief Executive Officer and Executive Chairman of the Company
Joel Kleiner (aged 36) was appointed Chief Financial Officer of the Company.
Yehuda Levy ceased to be the Company’s Interim Chief Executive Officer.
Effective February 13, 2025, Richard Perez was terminated as Chief Financial Officer of Algorhythm Holdings, Inc.
On February 13, 2025, the Board of Directors (the “Board”) of the Company appointed Alex Andre (age 50) as Chief Financial Officer and General Counsel of the Company.
the Board of Directors (the “Board”) of Fluor Corporation (the “Corporation”) appointed Mr. James R. Breuer as Chief Executive Office of the Corporation, effective May 1, 2025.
The Company previously announced the appointment of Tom Siragusa as interim chief financial officer, interim principal financial officer and interim principal accounting officer effective February 16, 2025.
the Company and Sergio Cervantes, the Chief Financial Officer of the Company agreed that Mr. Cervantes’ employment would be terminated, effective February 16, 2025
On February 18, 2025, the Board of Directors (the “Board”) of Solo Brands, Inc. (the “Company”) appointed John P. Larson, a member of the Board, as the Company’s Interim President and Chief Executive Officer, effective immediately.
On February 12, 2025, Flavia B. Landsberg, Executive Vice President and Chief Financial Officer of Pyxus International, Inc. (the "Company"), resigned from her positions with the Company effective February 28, 2025 to accept employment with another company.
On February 13, 2025, the Company’s Board of Directors appointed Dustin L. Styons, Executive Vice President, Business Strategy & Sales of the Company, as the Company’s Interim Chief Financial Officer, effective on February 28, 2025.
the Board of Directors elected Mr. Eric A. Clark to succeed Mr. Eddie Capel as President and Chief Executive Officer of the Company, to be effective February 12, 2025.
On February 11, 2025, the Board appointed Thi La, the Company’s current President and Chief Operating Officer, to serve as Chief Executive Officer, effective July 1, 2025.
On February 10, 2025, Andrew J. Paul notified Corsair Gaming, Inc. (the “Company”) of his retirement from his position as Chief Executive Officer and from the board of directors of the Company (the “Board”), effective July 1, 2025.
On February 12, 2025, Richard Joel Paolone was appointed to serve as Interim Chief Executive Officer of the Company and Chairman of the Board, effective immediately.
On February 12, 2025, the Board of Directors (the “Board”) of Entero Therapeutics, Inc. (the “Company”) terminated James Sapirstein as Chief Executive Officer of the Company, without cause, effective immediately.
On February 14, 2025, the Board of Directors of the Company, appointed Alexander Shen, the Company’s Chief Executive Officer to serve as the interim principal financial officer and principal accounting officer of the Company
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.